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Abstract
Background: Hemostasis and thrombosis are regulated by agonist-induced activation of platelet integrin aIIbb3. Integrin
activation, in turn is mediated by cellular signaling via protein kinases and protein phosphatases. Although the catalytic
subunit of protein phosphatase 1 (PP1c) interacts with aIIbb3, the role of PP1c in platelet reactivity is unclear.
Methodology/Principal Findings: Using c isoform of PP1c deficient mice (PP1cc
2/2), we show that the platelets have
moderately decreased soluble fibrinogen binding and aggregation to low concentrations of thrombin or protease-activated
receptor 4 (PAR4)-activating peptide but not to adenosine diphosphate (ADP), collagen or collagen-related peptide (CRP).
Thrombin-stimulated PP1cc
2/2 platelets showed decreased aIIbb3 activation despite comparable levels of aIIbb3, PAR3, PAR4
expression and normal granule secretion. Functions regulated by outside-in integrin aIIbb3 signaling like adhesion to
immobilized fibrinogen and clot retraction were not altered in PP1cc
2/2 platelets. Thrombus formation induced by a light/
dye injury in the cremaster muscle venules was significantly delayed in PP1cc
2/2 mice. Phosphorylation of glycogen
synthase kinase (GSK3)b-serine 9 that promotes platelet function, was reduced in thrombin-stimulated PP1cc
2/2 platelets
by an AKT independent mechanism. Inhibition of GSK3b partially abolished the difference in fibrinogen binding between
thrombin-stimulated wild type and PP1cc
2/2 platelets.
Conclusions/Significance: These studies illustrate a role for PP1cc in maintaining GSK3b-serine9 phosphorylation
downstream of thrombin signaling and promoting thrombus formation via fibrinogen binding and platelet aggregation.
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Introduction
Agonist-induced platelet activation is critical for maintaining
hemostasis at the site of vascular injury. Activation of platelets also
contributes to the process of thrombosis following the rupture of
atherosclerotic plaques. Thrombin generated at the site of injury
binds to protease activated receptors (PAR)1 or PAR4 on human or
mouse platelets, triggers protein phosphorylation on serine/
threonine (Ser/Thr) residues and facilitates integrin aIIbb3 activation
[1]. In particular, Ser/Thr kinases such as mitogen-activated protein
kinase (MAPK) [2], protein kinase G (PKG) [3,4], protein kinase B/
AKT [5,6], protein kinase C a (PKC a)[ 7 ] ,P K Ch [8] and glycogen
synthase kinase 3b (GSK3b) [9] play a key role in aIIbb3 activation
by thrombin or PAR4 activating peptide (PAR4-AP). Importantly,
thrombin-induced and Ser/Thr kinase–mediated activation of
signaling circuitry in platelets is reversible. Since protein phospha-
tases can fine-tune kinase-mediated signaling processes, we hypoth-
esized that Ser/Thr phosphatases participate in hemostasis/
thrombosis by regulating agonist-induced platelet activation.
Platelets express several Ser/Thr phosphatases, and a pool of
the catalytic subunits of protein phosphatase 1 (PP1c) and protein
phosphatase 2A (PP2Ac) associates with integrin aIIbb3 [10,11].
Generic Ser/Thr phosphatase inhibitors like okadaic acid and
calyculin A inhibited agonist-induced platelet aggregation, secre-
tion [12–14], adhesion and spreading to immobilized fibrinogen
[15]. Since these pharmacological agents inhibit several closely
related phosphatases (namely, PP1, PP2A and PP4) [16], it is
difficult to interpret the specific contribution of protein phospha-
tase 1 (PP1) and/or its isoforms in agonist-induced integrin aIIbb3
signaling. Our goal was to address a role for PP1 in platelets using
a genetic approach.
PP1 is a major eukaryotic Ser/Thr protein phosphatase that
regulates a variety of functions like glycogen metabolism, muscle
contraction, transcription, translation and cell division [17,18].
PP1 is a multimeric enzyme formed by the assembly of catalytic
and regulatory subunits. PP1c is a 35–38 kDa protein that exists as
three isoforms: a, b/d and c sharing greater than 90% amino acid
sequence similarity. Two splice variants of PP1cc (PP1cc1 and
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8304PP1cc2) have also been identified. All PP1c isoforms are
ubiquitously expressed, except for PP1cc2 that is testis specific.
Cellular PP1 activity is regulated by multiple factors: 1) reversible
phosphorylation of the regulatory subunits 2) dissociation of the
regulatory and the catalytic subunits 3) allosteric regulation of the
regulatory subunits and 4) inducible expression of the regulatory
subunits [17].
Among the various isoforms of PP1c, mice bearing a targeted
deletion of the gene for PP1cc [Ppp1cc
2/2]a r ev i a b l ea n da r e
considered in this study [19]. Using PP1cc
2/2 platelets, we
report a moderate decrease in low dose thrombin-induced aIIbb3
activation, soluble fibrinogen binding, platelet aggregation and
thrombus formation. GSK3b-Ser9 phosphorylation that
promotes platelet function was also decreased in thrombin-
stimulated PP1cc
2/2 platelets. GSK3b inhibitor partially
abrogated the difference in fibrinogen binding between throm-
bin-stimulated wild type and PP1cc-/- platelets. These studies
suggest a positive role for PP1cc in thrombin-induced platelet
functional responses.
Materials and Methods
Materials
Unless stated, all reagents were from Sigma-Aldrich (St. Louis,
MO). Fluorescein isothiocyanate (FITC)-conjugated antibodies
(anti-mouse CD41 (aIIb) and CD62 (P-selectin) were from BD
Bioscience (San Jose, CA). Phycoerythin-conjugated JON/A
(recognizes activated murine aIIbb3) and thrombin were gifts from
Dr. B. Nieswandt (University of Wurzburg, Germany) and Dr. J.
Fenton (New York State Department of Health, Albany),
respectively. ADP and collagen were from Helena Laboratories
(Beaumont, TX). GSK3b inhibitor VIII was from Calbiochem
EMD4Biosciences (Darmstadt, Germany). Protease-activated re-
ceptor 4-activating peptide (PAR4AP) AYPGKF was synthesized
by the Protein Core Facility at Baylor College of Medicine.
Collagen-related peptide (CRP) was synthesized at Baylor College
of Medicine and cross-linked by glutaraldehyde. Alexa 488-
conjugated fibrinogen was from Invitrogen, (Carlsbad, CA) while
human fibrinogen was from Enzyme Research Laboratories Inc.
(South Bend, IN). Antibodies to phospho-AKT Ser473, phospho-
GSK3b Ser9 and AKT were obtained from Cell signaling (Boston,
MA). Antibodies to thea, and c isoforms of PP1c, PAR3 and
PAR4 were purchased from Santacruz Biotechnology (Santacruz,
CA). b isoform of PP1c was from Upstate Biotechnology/
Millipore (Billerica, MA).
Mice Platelet Preparation
All animal studies were approved by the Institutional Animal
Care and Use Committee at Baylor College of Medicine. CD-1
mice carrying the PP1cc targeted deletion [19] and subsequently
backcrossed for 10 generations onto Balb/C background were
obtained from Dr. S. Varmuza (University of Toronto). For most
studies, 8–14 weeks old wild type (WT) and PP1cc
2/2 littermate
mice matched for age and gender were used. Blood was collected
from the inferior vena cava of isoflurane-anesthetized mice into
acid-citric acid-dextrose (ACD) at a ratio of 1:10 (vol/vol). Whole
blood was further diluted with an equal volume of Dulbecco’s
phosphate buffered saline (D-PBS) (Invitrogen), [2.6 mM KCl,
1.4 mM KH2PO4, 137 mM NaCl, 8 mM Na2HPO4] containing
ACD (1:9 parts ACD/D-PBS). Platelet rich plasma (PRP) was
obtained by centrifugation of the diluted blood at 68 g for 10
minutes at room temperature. PRP was further centrifuged at
754 g for10 minutes and the resulting platelet pellet was washed
once in D-PBS and resuspended in D-PBS containing 0.005 U/ml
apyrase to avoid desensitization of ADP receptors. Platelets were
counted using a Coulter counter (Beckman-Coulter (Z1), Miami,
FL) and adjusted to a final concentration of 2.5610
8/ml and then
allowed to rest for at least 1 hour.
Immunoblotting Studies
Resting platelets were lysed with 1% Triton X-100 containing
lysis buffer supplemented with a cocktail of protease and
phosphatase inhibitors. Forty mg of protein lysate were resolved
on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblotted with antibodies to different
isoforms of PP1c, PAR3, PAR4 and actin. In some experiments,
washed platelet treated with varying concentrations of thrombin
for 2 minutes were lysed and immunoblotted with antibodies to
phospho-AKT Ser 473, phospho-GSK3b Ser9, and AKT.
Binding of primary antibodies were detected by HRP-conjugated
secondary antibodies developed using ECL-system (Amersham
Biosciences).
Fibrinogen Binding, Flow Cytometry Analysis and Platelet
Aggregation
To study fibrinogen binding, washed platelets were diluted to a
concentration of 2.5610
7/ml with Tyrode’s buffer containing
1.8 mM CaCl2 and 0.49 mM MgCl2. Platelets were stimulated
with various concentrations of the following agonists: thrombin
(0.005, 0.01, 0.02, 0.1 U/ml), adenosine diphosphate (ADP) (5, 10,
20 mM), collagen (1, 2.5 and 5 mg/ml), collagen-related peptide
(CRP) (0.1, 0.2 mg/ml), PAR4-AP (100, 500 mM) followed by
addition of Alexa 488-conjugated fibrinogen (50 mg/ml final
concentration) at room temperature for 15–20 minutes. In some
studies, platelets were pretreated with control (DMSO) or 10 mM
GSK3b inhibitor VIII for 30 minutes before stimulation with
thrombin (0.02 U/ml). In other studies, platelets (resting or
thrombin-stimulated) were incubated with FITC-conjugated
anti-mouse CD41, PE-conjugated anti-mouse GPIba, PE-labeled
JON/A, and FITC-conjugated anti-mouse P-selectin antibodies to
detect aIIbb3, GPIba expression, activation of integrin aIIbb3, and
a granule secretion, respectively. Fluorescence-activated cell
sorting (FACS) analysis of platelets was performed using an
EPICS-XL flow cytometry (Beckman Coulter). Platelet aggrega-
tion in response to various agonists was initiated by addition of
various agonists to a 225 ml aliquot of washed platelets in a four
channel Bio/Data PAP-4C aggregometer (Biodata Corporation,
Horsham, PA)
Platelet Adhesion and Clot Retraction
Ninety six well plates were coated with 100 mg/ml of fibrinogen
and blocked with 5 mg/ml of Bovine Serum Albumin (BSA).
Control wells were coated with only BSA. Fibrinogen or BSA
coated wells were incubated with 1610
7 washed platelets in D-
PBS supplemented with 1.8 mM CaCl2 and 0.49 mM MgCl2 for
varying time periods at 37uC. Unbound platelets were washed and
the attached platelets were quantified by assaying for acid
phosphatase activity at 405 nM. The number of platelets attached
was obtained by using a standard curve for absorbance versus cell
number. Fibrin-clot retraction, was initiated by the addition of
1 U/ml thrombin to 150 ml of mouse platelet-rich plasma
containing (2.5610
8 platelets/ml) supplemented with 3 mM
CaCl2. After incubating at RT for varying time periods, the
amount of liquid not incorporated into the clot is measured. The
volume of the clot was determined by subtracting the measured
volume from 150 ml (initial volume). Clot volume was expressed as
a percentage of the initial volume.
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Microvascular thrombosis was examined in the cremaster
venules using a previously well described model of light/dye –
induced endothelial injury by intravital microscopy [20,21].
Briefly, male mice anesthetized with 50 mg/kg phenobarbital
sodium were placed on a custom plexiglas tray maintained at 37uC
with a homeothermic blanket. To assist in breathing, a
tracheotomy was performed. Later, an internal jugular vein and
common carotid artery were cannulated to facilitate administra-
tion of various preparations and monitoring of blood pressure/
heart rate, respectively. The cremaster microvascular bed was
prepared, perfused with bicarbonate-buffered saline solution (pH
range, 7.35–7.45) at 35uC and transferred to the stage of an
upright intravital video microscope (BX-50; Olympus, Tokyo,
Japan). After equilibration for 30 minutes, 10 mL/kg 5% FITC-
labeled dextran (150 kD) was injected intravenously through the
jugular vein. A suitable venule was selected after survey of the
vascular bed with a 46 objective (NA 0.13) lens. Following the
measurement of the diameter and blood flow velocity of the vessel
(Doppler velocimeter; Microcirculation Research Institute, Col-
lege Station, TX), a photochemical injury was initiated by
exposing approximately 100 mm of the vessel to filtered excitation
light at 0.6 W/cm
2 (from a 175W xenon lamp; Sutter Instrument,
Novato, CA; and an HQ-FITC filter cube; Chroma Technology,
Brattleboro, VT). Epi-illumination was applied continuously, and
the time of onset of platelet aggregates (thrombus onset) and the
time of flow cessation (for at least 60 seconds) were monitored and
recorded using a 406water-immersion objective (NA 0.8) by an
observer who was blinded to the genotype of the animals.
Thrombi were induced in 1–2 venules per animal, and the results
for each animal were averaged.
Tail-Bleeding Times
Tails of anesthetized mice (WT and PP1cc
2/2) were severed
with a scalpel 1 mm from the tip and immediately immersed in a
tube containing PBS solution at 37uC. Thirty seconds later, the tail
was immersed into a new tube with PBS and this process of
transferring the tail to a new tube was repeated until the bleeding
stopped. The time from the incision to cessation of blood (as
revealed by visual examination of blood in the tubes) were
recorded as tail bleeding times.
Statistical Analysis
Results are expressed as means +/2 SEM. Experimental
conditions were compared by using paired student’s t test.
Results
PP1cc
2/2 Platelets Exhibited Comparable Expression of
Other PP1c Isoforms
Immunoblotting studies with an antibody specific for the c
isoform of PP1c confirmed the absence of PP1cc protein in
PP1cc
2/2 platelets (Figure 1C). Furthermore, there was no
evidence for a compensatory up-regulation of a and b isoforms
of PP1c in the platelets from PP1cc
2/2 mice (Figure 1A and 1B).
These blots were stripped and reprobed with actin to ensure equal
protein loading (Figure 1 A, Band C lower panel).
PP1cc
2/2 Platelets Exhibited a Mild Agonist-Specific
Impairment in Fibrinogen Binding and Aggregation
To determine if the loss of Ppp1cc gene affected platelet
reactivity washed platelets from the WT and PP1cc
2/2 mice were
stimulated with platelet agonists and analyzed for soluble
fibrinogen binding. Low concentrations of strong agonists like
thrombin, collagen and dilute suspension of platelets were used to
ensure that platelets did not aggregate in this assay. ADP, collagen
and CRP induced-soluble fibrinogen binding were comparable
between the WT and PP1cc
2/2 platelets (Figure 2A). In contrast,
addition of low doses of thrombin to PP1cc
2/2 platelets resulted
in a modest but significant decrease in the soluble fibrinogen
binding. A ,42% (p=0.02) and ,45% (p=0.01) decreased
fibrinogen binding in response to 0.01 U/ml and 0.02 U/ml of
thrombin was observed in PP1cc
2/2 platelets (Figure 2B).
However, the difference in fibrinogen binding between WT and
Figure 1. PP1c isoforms in platelets. (A–C) Platelet lysate from wild
type (WT) or PP1cc
2/2 mice were evaluated by SDS-PAGE and Western
blotting using isoform specific antibodies to a, b and c (recognizes c1
and c2 splice variants). These membranes were stripped and reprobed
with actin to demonstrate equal protein loading (lower panels). Blots
are representative of three independent experiments.
doi:10.1371/journal.pone.0008304.g001
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2/2 platelets. Washed platelets from
WT or PP1cc
2/2 mice were stimulated with ADP, collagen or CRP (A), thrombin (B) or PAR4-AP (C) in the presence of Alexa 488 fibrinogen and bound
fibrinogen analyzed by flow cytometry as mean fluorescence intensity (MFI). Data are 6SEM of 9–11 experiments for ADP, thrombin and collagen and
13–14 experiments for PAR4-AP. As compared to the WT platelets, the decreased fibrinogen binding in PP1cc
2/2 platelets were significant at
*p=0.02 (for 0.01 U/ml thrombin); #p=0.01 (for 0.02 U/ml thrombin); *p=0.05 (for 200 mM PAR4-AP). In other experiments (n=3), platelets were
pretreated with 0.5 mM EDTA or 2 mM apyrase (ADP scavenger) prior to stimulation with 0.02 U/ml thrombin. (D) Percentage aggregation for WT
and PP1cc
2/2 platelets in response to the indicated doses of thrombin, ADP and collagen. Studies are indicated as 6SEM of 5–6 experiments. The
decreased aggregation in 0.02 U/ml thrombin stimulated PP1cc
2/2 platelets compared to WT platelets was significant at *p=0.04.
doi:10.1371/journal.pone.0008304.g002
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2/2 platelets was lost with increasing concentrations of
thrombin (not shown). Addition of cation chelator EDTA known
to block aIIbb3 function inhibited fibrinogen binding in WT and
PP1cc
2/2 platelets to values obtained in unstimulated platelets.
Many, but not all responses of thrombin in human platelets could
be reproduced by thrombin receptor activating peptide [22–24].
To explore whether PP1cc participated in thrombin signaling
downstream of mouse thrombin receptor PAR4, we stimulated
platelets with protease-activated receptor 4 activating peptide
(PAR-4AP) and assessed fibrinogen binding. Compared with wild
type platelets, PP1cc
2/2 platelets showed only marginally
decreased soluble fibrinogen binding in response to PAR-4AP
(P=0.05) (Figure 2C).
Soluble fibrinogen binding under stirring conditions can lead to
platelet aggregation. Next, we determined whether platelet
aggregation in response to agonist was altered in PP1cc
2/2
platelets. Compared with WT platelets, PP1cc
2/2 platelets
demonstrated ,60% decreased aggregation to 0.02 U/ml
thrombin. Aggregation in response to ADP and collagen was
comparable between the WT and PP1cc
2/2 platelets (Figure 2D).
Since moderate differences in soluble fibrinogen binding and
aggregation between the WT and PP1cc
2/2 platelets were
noticed only at low thrombin concentrations and not with other
agonists, we conducted the rest of the studies in this report with
only low dose thrombin.
PP1cc
2/2 Platelets Exhibited Decreased
Thrombin-Induced Activation of aIIbb3 despite Normal
Expression of aIIbb3, Thrombin Receptors and Normal
Granule Secretion
To identify potential mechanisms for the decreased reactivity in
thrombin stimulated PP1cc
2/2 platelets, we analyzed the
expression of thrombin receptors PAR3 and PAR4. Because
reliable antibodies that detect PAR4 by immunofluoresence were
not readily available, we subjected platelet lysate to immunoblot-
ting experiments with anti-PAR3 and PAR4 antibodies. Compa-
rable expression of PAR3 and PAR4 receptors was observed
between the WT and PP1cc
2/2 platelets (Figure 3A). Besides
PARs, GPIba serves as high affinity thrombin binding site [25].
However, GPIba expression was not different in WT and
PP1cc
2/2platelets (data not shown). Next, we studied the
activation status of integrin aIIbb3 in thrombin-stimulated WT
and PP1cc
2/2 platelets by flow cytometry using a murine aIIbb3
activation–specific JON/A antibody. Under resting conditions,
there was no difference in JON/A binding between the WT and
PP1cc
2/2 platelets. In contrast, addition of thrombin (0.02 U/
ml) to PP1cc
2/2 platelets resulted in a moderate but significant
decrease in JON/A binding (Figure 3B). Expression levels of aIIbb3
in the resting and thrombin stimulated platelets were comparable
in the WT and PP1cc
2/2 mice (Figure 3C). This indicates that the
decreased JON/A binding in thrombin stimulated PP1cc
2/2
platelets were not due to the altered integrin expression. Potential
alterations in platelet granule secretion events in PP1cc
2/2 mice
could account for the decreased aIIbb3 activation at low doses of
thrombin. However, secretion of P-selectin (a granule content) was
not altered between WT and PP1cc
2/2 platelets (Figure 3D).
Furthermore, addition of exogenous fibrinogen did not rescue the
decreased aggregation of thrombin stimulated PP1cc
2/2 platelets
(not shown). ADP scavenger apyrase did not abolish thrombin-
induced fibrinogen binding difference between the WT and
PP1cc
2/2 platelets (Figure 2B). This observation suggests that the
fibrinogen binding difference between the WT and PP1cc
2/2
platelets is not dependent on dense granule ADP. Thus, these
studies suggest that decreased aIIbb3 activation and not altered
receptor expression or granule secretion may have contributed to
the decreased fibrinogen binding in thrombin-treated PP1cc
2/2
platelets.
PP1cc
2/2 Platelet Exhibited Normal Outside in Integrin
aIIbb3 Signaling
We assessed if functions mediated by outside-in integrin aIIbb3
signaling were altered in the PP1cc
2/2 mice. In contrast to the
data from soluble fibrinogen, adhesion of PP1cc
2/2 platelets to
immobilized fibrinogen was comparable to the WT platelets
(Figure 4A). Thrombin-induced clot retraction of platelet rich
plasma samples was also not altered between the WT and
PP1cc
2/2 mice (Figure 4B). Collectively, these studies imply that
outside-in integrin aIIbb3 signaling processes were not altered by
the lack of PP1cc in platelets.
PP1cc
2/2 Mice Exhibited Delayed Thrombus Formation
in a Light-Dye Injury Thrombosis Model
To establish if the defect in PP1cc
2/2 platelets observed in vitro
might affect thrombus formation in vivo, we studied the responses
of WT and PP1cc
2/2 mice to a light/dye-induced injury model
that has been previously shown not to denude the endothelium
[20]. The initiation time for thrombus formation was not different
between the WT and PP1cc
2/2 mice (Fig. 5A). In contrast, we
noticed a moderate but significant (P=0.03) delay in the time for
complete cessation of blood flow (occlusion time) in PP1cc
2/2
mice (Fig. 5A). Microvascular diameter and wall shear rate was
comparable between the WT and PP1cc
2/2 mice (23.360.3 mm
vs. 24.660.5 mm and 515628 sec
21 vs. 516629 sec
21, respec-
tively). Similarly, blood pressure and heart rate was not
significantly different between the WT and PP1cc
2/2 mice
(82.861.9 mmHg vs. 81.5621. mmHg and 436614 min
21 and
465612 min
21, respectively) suggesting that the delayed throm-
bus formation in PP1cc
2/2 mice was independent of these above
mentioned factors. Thus, in this thrombosis model, PP1cc
participates modestly in stabilizing thrombus formation. In
contrast, tail bleeding times were not different between the WT
and PP1cc
2/2 mice (Figure 5B).
Thrombin-Stimulated PP1cc
2/2 Platelets Exhibited
Decreased Glycogen Synthase Kinase3 b -Serine 9
Phosphorylation in an AKT Independent Manner
Platelet functional responses to thrombin are mediated in part
by activation of signaling molecules in the PI3K-AKT-GSK-3b
circuitry. Interestingly, there exist some similarly in the phenotype
of PP1cc
2/2 mice when compared to AKT2
2/2, AKT1
2/2 and
GSK3b
+/2 mice. All four null mice predominantly showed
thrombin or PAR4 specific impairment in platelet function except
AKT1
2/2 mice, which also exhibited defects in platelet responses
to collagen [6]. Therefore, we investigated if PP1cc regulates
thrombin-induced signaling to AKT. Activation of AKT as
measured by phosphorylation of AKT-Ser473 was comparable
between the thrombin stimulated WT and PP1cc
2/2 platelets
(Figure 6A and 6B). Next, we assessed the activation of GSK3b
(AKT substrate) because PP1 can regulate GSK-3b Ser9
phosphorylation, independent of AKT, under in vitro conditions
[26]. GSK3b is a suppressor of platelet function and agonist–
induced Ser9 phosphorylation decreases GSK3b kinase activity
and promotes platelet function [9]. Consistent with the earlier
report [9], thrombin stimulation in WT platelets resulted in
sustained phosphorylation of GSK-3b-Ser9. Unexpectedly, throm-
bin-stimulated PP1cc
2/2 platelets showed a maximum of ,1.9
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observations imply a role for PP1cc in GSK-3b-Ser9 phosphor-
ylation downstream of thrombin signaling by an AKT indepen-
dent pathway. It should be emphasized that although a majority of
PAR4-stimulated GSK3b-Ser9 phosphorylation was previously
shown to be dependent on PI3K/AKT signaling, the same study
also reported a fraction of GSK3b-Ser9 phosphorylation that was
independent of PI3K/AKT pathway [9]. Thus, a pathway
involving PP1cc might represent one of the non-AKT dependent
mechanisms that could potentially regulate GSK3b-Ser9 phos-
phorylation.
Since GSK3b-Ser9 phosphorylation inhibits the constitutive
GSK3b activity, we examined whether the decreased GSK3b-
Ser9 phosphorylation (active GSK3b) upon thrombin stimula-
tion could contribute to the decreased fibrinogen binding in
PP1cc
2/2 platelets. Compared with WT platelets, PP1cc
2/2
platelets exhibited ,40% decreased fibrinogen binding upon
stimulation with 0.02 U/ml thrombin in the presence of
DMSO (control). However, in the presence of GSK3b inhibitor
VIII, PP1cc
2/2 platelets exhibited ,23% decreased fibrino-
gen binding compared to the WT platelets, suggesting that the
difference in fibrinogen binding between the thrombin-
stimulated WT and PP1cc
2/2 platelets were partially
abolished by GSK3b inhibitor. Thus, these studies imply that
GSK3 activity, in part, contributes to the decreased fibrinogen
binding in PP1cc
2/2 platelets.
Discussion
Compared with Ser/Thr kinases, a specific role for PP1cc in
platelet activation is unclear. Although a compensatory up-
regulation of PP1ca and PP1cb isoforms was not particularly
evident in PP1cc
2/2 platelets, a potential redundancy between
the individual PP1c isoforms in PP1cc
2/2 platelet function is
Figure 3. Expression of thrombin receptors, aIIbb3 and P-selectin in PP1cc
2/2 platelets. (A) Lysate from resting washed platelets was
evaluated by SDS-PAGE and immunoblotted with anti-PAR3 antibody (,43 kDa). The blot was stripped and reprobed with anti- PAR4 (,38 kDa) and
then with anti-actin (loading) antibodies. Blots are representative of two experiments. Washed platelets were incubated with anti-JON/A PE antibody
(B) or anti-aIIb FITC antibody (C) or anti-P-selectin antibody (D) and subjected to flow cytometry. Results are expressed as 6SEM of 5–6 experiments.
Compared to thrombin stimulated WT platelets, the decreased binding of JON/A antibody to PP1cc
2/2 platelets was significant at *p=0.003.
doi:10.1371/journal.pone.0008304.g003
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seen in PP1cc
2/2 mice. Despite this constrain, our studies
uncovers two novel aspects of PP1cc with regards to the
platelet biology. 1) PP1cc regulates low dose thrombin-induced
integrin aIIbb3 activation, soluble fibrinogen binding, platelet
Figure 4. Outside-in integrin aIIbb3 signaling functions in
PP1cc
2/2 platelets. (A). Washed platelets were incubated with
immobilized fibrinogen-coated micro titer wells for the indicated
periods of time and adhesion quantified. The data are expressed as
6SEM of 3 experiments. (B) Fibrin clot retraction was examined
following the addition of thrombin to platelet-rich plasma. Volume of
the clot is expressed as 6SEM of 3 experiments.
doi:10.1371/journal.pone.0008304.g004
Figure 5. Role of PP1cc in thrombosis and hemostasis injury
models. (A). Light/dye -induced microvascular thrombosis was studied
in the venules of the cremaster muscles of WT and PP1cc
2/2 mice by
intra vital microscopy. The onset of thrombosis (onset) and the
cessation of blood flow following the injury were monitored. Results
are expressed as 6SEM of 13 experiments. Compared to the WT, the
delayed time for flow cessation in PP1cc
2/2 mice was significant at
*p=0.03. (B). Tail vein bleeding times from 13 WT and PP1cc
2/2 mice
are shown.
doi:10.1371/journal.pone.0008304.g005
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2/2 platelets. (A). Platelet lysate from resting (0) and
thrombin activated (0.005, 0.01 and 0.02 U/ml) was separated on an SDS-PAGE and immunoblotted with antibodies to AKT-Ser473, GSK3b- Ser9 and
AKT (total). (B and C) Densitometric quantification of phosphorylation levels for AKT-Ser473 and GSK3b-Ser9 in WT and PP1cc
2/2 stimulated
platelets. The decreased phosphorylation of GSK3b-Ser9 in thrombin-stimulated PP1cc
2/2 platelets was significant at ¤p=0.05 (for 0.01 U/ml
thrombin); *p=0.02 (for 0.02 U/ml thrombin). Data are expressed as 6SEM of 5 experiments. (D) Effect of GSK3b inhibitor VIII on thrombin-induced
fibrinogen binding on WT and PP1cc
2/2 platelets. Compared with WT platelets, PP1cc
2/2 platelets displayed ,40% decreased fibrinogen binding in
response to 0.02 U/ml thrombin in the presence of solvent control (DMSO) (*P=0.048) and GSK3 inhibitor VIII (GSK3b) partially reduced the
difference to 23%. Data are expressed as 6SEM of 3–4 experiments.
doi:10.1371/journal.pone.0008304.g006
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for a sustained thrombin-stimulated GSK3b-Ser9 phosphory-
lation in platelets.
Targeted disruption of the Ppp1c gene in mice led to impaired
spermiogenesis and male infertility [19]. Although PP1cc is more
intensely studied in the area of reproductive biology, our studies
indicate that PP1cc can also regulate platelet activation in an
agonist-specific manner. In particular, a subtle role for PP1cc was
noted in aIIbb3 activation, fibrinogen binding and aggregation
response to low dose thrombin but not to ADP, collagen and CRP
(Figures 2). Perhaps, activation of multiple redundant signaling
pathways by higher concentrations of thrombin and/or other
agonists might favor activation of PP1ca or PP1cb in the absence
of PP1cc to sustain activation of platelets. More importantly,
thrombus formation induced by light-dye injury was significantly
delayed in the cremasteric venules of the PP1cc
2/2 mice
(Figure 5A). Since PP1cc
2/2 is not a platelet specific knockout,
contribution of PP1cc from other cell types within the vasculature
towards in vivo thrombosis cannot be ruled out. Nevertheless, this in
vivo study is consistent and correlates well with the in vitro platelet
data. In contrast to the thrombosis model, normal hemostasis was
not altered in PP1cc
2/2 mice as revealed by normal tail bleeding
times (Figure 5B). It is not known whether the differential role
played by PP1cc in hemostasis versus thrombosis models was due
to the intrinsic differences in the type and extent of injury in the
two models, or due to the compensatory mechanisms, which was
sufficient to drive hemostasis but not thrombosis.
Previous studies have identified that outside-in integrin aIIbb3
signaling mechanisms facilitated the dissociation of aIIbb3 bound
PP1c, with the ability to dephosphorylate platelet myosin light
chain (MLC) [10]. Following the engagement of integrin aIIbb3,
PP1cc was shown to be involved in the dephosphorylation of
ADP-induced nPKCg activation [27]. These observations imply
that PP1cc might regulate platelet functions mediated by outside-
in integrin aIIbb3 signaling processes. However, outside-in integrin
aIIbb3 signaling dependent functions like adhesion and spreading
(not shown) to immobilized fibrinogen and clot retraction were not
altered in PP1cc
2/2 mice. Since all PP1c isoforms can interact
with aIIbb3 (unpublished observation), one possibility is that the
PP1cc isoform does not participate in the functional responses
initiated by outside-in integrin aIIbb3 signaling. Indeed, platelet
MLC is dephosphorylated by PP1cb/d (myosin phosphatase) but
not PP1cc [28]. Another possibility relates to an easy compensa-
tion by other PP1c isoforms following engagement of integrin
aIIbb3 to alter platelet outside-in signaling functions. Finally, the
platelet functional data from PP1cc
2/2 mice was not completely
consistent with the studies in human platelets treated with Ser/Thr
protein phosphatase inhibitors. The latter studies employed
calyculin A and okadaic acid and observed inhibition of platelet
aggregation and secretion to various agonists and adhesion to
immobilized fibrinogen [12–15]. These differences may stem from
the fact that the platelet phenotype obtained in response to the
pharmacological agents might be due to inhibition of multiple
phosphatases as opposed to inhibition of only PP1cc in this study.
Decreased platelet responses to thrombin observed in the
PP1cc
2/2 mice was not due to altered expression of PAR3,
PAR4, aIIbb3 or decreased platelet counts. In fact, we noticed a
moderate but significant increase in platelet numbers in PP1cc
2/2
mice [Mean6SEM 596.78610
3/mm
3617.94 in WT compared
with 693.71610
3/mm
3619.87 in PP1cc
2/2 mice; N=12,
P=0.0003]. However, we cannot rule out the possibility that the
lack of PP1cc isoform could alter PAR4 activation associated
proximal signaling events such as binding of GTP to the G
proteins that couple to PAR4. Perhaps, multiple substrates of
PP1cc may exist in the signaling pathways that control aIIbb3
activation downstream of thrombin signaling. Absence of PP1cc
may alter the phosphorylation of one or more of these cellular
proteins, thereby suppressing the platelet function. In fact, we
noticed that the GSK3b-Ser9 phosphorylation was significantly
reduced in thrombin stimulated PP1cc
2/2 platelets (Figures 6A
and 6C). GSK3b is Ser/Thr kinase and phosphorylation of Ser9
residue inhibits its constitutively active kinase activity [29].
Although an initial study using a more generic and non selective
GSK3 inhibitor implied a positive role for GSK3b in platelet
function [30], a more recent comprehensive genetic analysis using
GSK3b heterozygote mice revealed that GSK3b is a negative
regulator of platelet function [9]. Results from the latter study
indicated that thrombin stimulated GSK3b Ser 9 phosphorylation
and removed the suppressive role of GSK3b on platelet function.
Thus, a decreased GSK3b-Ser9 phosphorylation upon thrombin
stimulation is predicted to maintain a constitutive GSK3b activity,
thereby inhibiting the platelet function. Indeed, our studies
revealed that the PP1cc
2/2 platelets stimulated with thrombin
had decreased GSK3b-Ser9 phosphorylation along with decreased
aIIbb3 activation, fibrinogen binding, aggregation and delayed
thrombus formation. Moreover, pharmacological inhibition of
GSK3b partially abolished the difference in fibrinogen binding
between WT and PP1cc
2/2 platelets (Figure 6D). These
observations suggest that additional mechanisms that underpin
the decreased fibrinogen binding in thrombin-stimulated
PP1cc
2/2 platelets exist and remain to be identified.
The molecular basis for the relationship between the loss of
PP1cc and decreased GSK3b-Ser9 phosphorylation is currently
unclear. PP1cc does not appear to directly dephosphorylate Ser9
on GSK3b, because GSK3b-Ser9 phosphorylation under basal
conditions was not significantly increased in PP1cc
2/2 platelets.
Although AKT has a major role in GSK3b Ser9 phosphorylation,
PP1cc does not appear to regulate GSK3b phosphorylation via
AKT, since we observed comparable level of AKT-Ser473
phosphorylation in thrombin stimulated WT and PP1cc
2/2
platelets. A potential for AKT independent regulation of
GSK3b-Ser9 phosphorylation was also noted in the previous
study [9]. Since PKC, PKA or p90Rsk can also phosphorylate
GSK3b at Ser(9) [31], it is likely that PP1cc could affect GSK3b
Ser9 phosphorylation by regulating the activation of one or more
of these Ser/Thr kinases. Alternatively, PP1cc may inhibit other
Ser/Thr phosphatases such as PP2A [32], which may participate
in dephosphorylating Ser9 on GSK3b under conditions of
thrombin stimulation thereby ensuring increased GSK3b-Ser9
phosphorylation.
In summary, our studies indicate that under conditions of low
thrombin stimulation, platelet PP1cc is required for GSK3b-Ser9
phosphorylation, aIIbb3 activation, soluble fibrinogen binding,
platelet aggregation and stabilization of thrombus formation. The
agonist specific role for PP1cc is intriguing and future studies will
be needed to address how PP1cc couples specifically to signaling
by PAR receptors and not to other G-protein coupled receptors.
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